Back to top

Also called the HIV Drug Resistance Study, MTN-009 assessed the prevalence of HIV drug resistance in KwaZulu-Natal, South Africa. Results, published in April 2013, found the prevalence of HIV drug resistance was 7.4 percent, with the majority of women with resistance having virus with the K103N mutation that confers resistance to most drugs of the type called non-nucleoside reverse transcriptase inhibitors (NNRTIs). Nevirapine, for example, an NNRTI commonly used to prevent the transmission of HIV from mother to child, would not be effective in someone with the K103N mutation.


MTN-009 Q&A



See Also

MTN-009 Study Protocol


MTN-009 Study Page